<DOC>
	<DOC>NCT00690365</DOC>
	<brief_summary>This is a single-arm, phase IV, open-label, prospective, non interventional study in approximately 600 patients that will be followed for 6 months in order to evaluate the safety and efficacy of quetiapine. Patients will be switched over a 4 to 7 day cross-titration period from their previous antipsychotic medication to quetiapine according to the approved SPC.</brief_summary>
	<brief_title>Safety and Efficacy of Switching to Quetiapine in Outpatients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Diagnosis of schizophrenia at least 1 year prior to screening Inadequate response or poor safety /tolerability or noncompliance to previous antipsychotic medication Provision of Informed Consent prior to enrolment Known hypersensitivity to active substance of excipients Patients receiving P450 3A4 inhibitors Pregnancy or lactation Substance abuse or dependence</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Switching</keyword>
	<keyword>Quetiapine</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>unsuccessfully treated</keyword>
	<keyword>antipsychotics</keyword>
</DOC>